Roswell Park Cancer Institute Cancer Vaccine Trial
Please Note:
At this time, we have accrued all the participants needed for the study. For information on other clinical research studies being offered at Roswell Park Cancer Institute, please visit http://www.roswellpark.org/clinical-trials/list.
To speak to a cancer information specialist for more information, please call 1-877-ASK-RPCI (1-877-275-7724).
You may wish to contact one of the resources below to see if there are any other appropriate clinical trials that are available in your area.
For out of state callers:
Contact the National Cancer Institute’s Cancer Information Services at 1-800-4-Cancer (1-800-422-6237) or the NIH Clinical Center at 1-800-411-1222.
For Canadian callers:
Contact the Canadian Cancer Society Research Institute at 1-416-961-7223.
For International callers:
Contact the Union for International Cancer Control at +41 22 809 1811.
What is the RPCI Cancer Vaccine Trial?
The purpose of this study is to test the safety of a treatment called DC205 NY ESO 1 vaccine, given with and without sirolimus, and to see what effects (good or bad) it has on you and your type of cancer. Find out if you may be eligible for the trial. Learn more about the study.
What is a Phase I Trial?
Phase I trials are the first step in testing a new approach in humans. In these studies researchers evaluate what dose is safe, how a new agent should be given (by mouth, injected into a vein, or injected into the muscle), and how often and what dose is safe. Researchers watch closely for any harmful side effects. Phase I trials usually enroll a small number of patients and take place at only a few locations. The patients are divided into small groups, called cohorts. Each cohort is treated with an increased dose of the new treatment or technique. The highest dose with an acceptable level of side effects is determined to be appropriate for further testing. Learn more about clinical trials.
About Kunle Odunsi, MD, PhD, FRCOG, FACOG
Dr. Adekunle "Kunle" Odunsi is Chair of the Department of Gynecologic Oncology, Director of the Center for Immunotherapy and Co-Leader of the Tumor Immunology and Immunotherapy research program at Roswell Park Cancer Institute. He joined RPCI's staff in 2001 as an Attending Surgeon in the Division of Gynecologic Oncology. After earning his medical degree from the University of Ife, Ile-Ife, Nigeria, in 1984, Dr. Odunsi completed postgraduate training in Obstetrics and Gynecology at the Rosie Maternity and Addenbrookes Hospitals, University of Cambridge, UK. Read more about Dr. Odunsi.
About Chris Choi, PhD
Dr. Yeong “Christopher” Choi is an Assistant Professor of Oncology and Director of the Center for Immunotherapy Good Manufacturing Practice (GMP) Therapeutic Cell Production Facility at Roswell Park. Dr. Choi has spent a decade in the development of cell and gene-based therapies to improve the medical outcome of life-threatening diseases. Read more about Dr. Choi.
Press Conference
Press Release
The Center for Immunotherapy at Roswell Park Cancer Institute (RPCI) has launched a phase I clinical research study of a dendritic cell vaccine designed to both eradicate cancer cells and prevent disease relapse.
Developed at RPCI, the NY-ESO-1 dendritic cell vaccine will be manufactured in the Institute’s new Therapeutic Cell Production Facility using a unique FDA-approved process — making RPCI the first research facility in the U.S. to use a custom-made barrier isolator for vaccine cell production, and the first in the world to use this system in an approved, government-regulated study. Read the full press release.
Around the Web
Testing a Defense Against Cancer
The Buffalo News
The Buffalo News
Pox Vaccines Extend Survival for Patients with Melanoma, Ovarian Cancer
MedicalExpress.com
MedicalExpress.com
The Immunity Boosters: A Conversation with Dr. Kunle Odunsi
